Gene therapy tracker
Approved disease-specific products belong in one bucket. Consumer age-reversal and reprogramming claims belong in a different, more cautious bucket.
FDA-approved cellular/gene therapies
| Item | Claims | Status | Evidence / risk | Source |
|---|---|---|---|---|
| FDA-listed approved cellular and gene therapy products Checked 2026-06-27 Related briefing | disease-specific treatment claims tied to named approved products | Approved only for specific products and indications | Evidence:Regulatory watchRisk:High riskStatus:Approved for this use FDA approval is product-specific. It should not be generalized to consumer rejuvenation claims. Indication drift, misunderstanding eligibility, adverse-event complexity. | FDA approved cellular and gene therapy products |
Investigational therapies
| Item | Claims | Status | Evidence / risk | Source |
|---|---|---|---|---|
| CRISPR and gene-editing trials Checked 2026-06-27 Related briefing | disease modification, one-time treatment potential | Trial-specific; check registry and FDA status | Evidence:Trial registeredRisk:ExperimentalStatus:Experimental Some gene-editing programs are in clinical development for specific diseases; aging claims need separate evidence. Off-target effects, delivery, immune response, durability. | ClinicalTrials.gov |
Longevity/reprogramming frontier items
| Item | Claims | Status | Evidence / risk | Source |
|---|---|---|---|---|
| Partial epigenetic reprogramming / OSK Checked 2026-06-27 Related briefing | cellular rejuvenation, age reversal, tissue repair | Frontier research; not consumer-available medicine | Evidence:Mostly lab/animalRisk:ExperimentalStatus:Experimental Compelling biology remains largely preclinical for longevity purposes. Cell identity loss, tumor biology, uncontrolled expression, delivery uncertainty. | PubMed |
Not consumer-available items
| Item | Claims | Status | Evidence / risk | Source |
|---|---|---|---|---|
| Consumer age-reversal gene therapy offers Checked 2026-06-27 Related briefing | broad rejuvenation, lifespan extension, age reset | Treat as unsupported unless tied to approved product or registered trial | Evidence:Commercial claimRisk:High riskStatus:Not approved Marketing claims should be downgraded unless the product, indication and evidence are transparent. Unregulated intervention, irreversible effects, financial harm, medical harm. | FDA gene therapy resources |